Guiding Novel Neurologic Drug Approvals
The FDA’s review of drug and biological products in this medication class is critical, as a brain impairment impacts between 6.5% and 7.9% of adults in the United States.
CMS Initiatives Regarding Pain-Management Issues
In 2018, CMS adopted a three-pronged approach to the public-health emergency posed by opioid use.
Benefits and Complications of Sodium-Glucose Cotransporter 2 Inhibitors
This drug class confers benefits in diabetic patients with heart failure, CV disease, and renal disease, but it is also associated with major adverse events.
Trends in Aspirin Use for Secondary Prevention of ASCVD
According to the CDC’s Behavioral Risk Factor Surveillance System 2013, nearly 71% of adults with atherosclerotic cardiovascular disease use aspirin regularly.
Copyright © 2000 - 2025 Jobson Medical Information LLC unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.